|
|
|
|
Ticagrelor Safer for ACS Patients Who May Need Urgent CABG
ATLANTA, GAAmong patients with acute coronary syndromes (ACS) who undergo coronary artery bypass grafting (CABG) within 7 days of stopping antiplatelet therapy, those who were receiving tricagrelor have better survival odds than those who were...
|
|
|
News and FDA Updates for AMAG (NASDAQ:AMAG), Anika (Nasdaq:ANIK), AstraZeneca (NYSE:AZN)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
Ticagrelor Shows Lower Mortality Than Clopidogrel After CABG
New Results from PLATO trial suggest ticagrelor (Brilinta) leads to lower mortality and no increased risk of bleeding when compared to clopidogrel (Plavix) in patients with acute coronary syndrome who undergo coronary artery bypass graft (CABG)...
|
|
|
Comparable patency achieved with radial artery and saphenous vein grafts
MedWire News: Study findings indicate that radial artery vein grafts provide comparable patency to saphenous vein grafts at 1 year after coronary artery bypass (CABG) graft surgery.The study was conducted at 11 centers between 2003 and 2008 and...
|
|
|
PLATO: Ticagrelor lowers total and CV mortality vs clopidogrel in CABG patients
MedWire News: Ticagrelor was associated with significantly lower total and cardiovascular mortality when compared with clopidogrel in acute coronary syndrome (ACS) patients undergoing coronary artery bypass graft (CABG) surgery, without any...
|
|
|
ACC: Long-Term Outcomes Similar for Stents and CABG
University of Pennsylvania School of Medicine.Action Points Explain to interested patients that this study did not find any significant differences on hard clinical endpoints between stenting and CABG for unprotected left main coronary artery disease....
|
|
|
ACC Feature: Saphenous vein grafts appear equal to radial artery grafts
ATLANTA--Saphenous vein grafts and radial artery grafts both result in equal graft opening at one year, according to a study presented as a late-breaking clinical trial Tuesday at the American College of Cardiologys (ACC) 59th annual scientific session.In...
|
|
|
Despite recommendations, nearly 14% of Medicare beneficiaries with STEMI undergo multi-vessel PCI
Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) undergo multi-vessel primary percutaneous coronary intervention (PCI), despite recommendations from the American College of...
|
|
|
AstraZeneca says PLATO study shows fewer deaths among heart bypass patients taking ticagrelor as compared to clopidogrel
AstraZeneca announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral antiplatelet BRILINTA...
|
|
|
Mayo Clinic Study Looks at How to Minimize Angioplasty Radiation Risks
Body size, gender and the complexity of heart disease significantly influence how much cumulative radiation skin dose patients receive during percutaneous coronary intervention (PCI) therapy, according to a new Mayo Clinic study.The study was...
|
|
|
OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy
OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.Margo Klomp, M.D., of the Academic Medical Center (AMC) in Amsterdam, presented the data...
|
|
|
More Research Needed to Determine Best Treatment of Multi-Vessel Coronary Artery Disease During Primary PCI for ST-Segment Elevation Myocardial Infarction
Companies mentioned in this article: Cardiac Data Solutions, Inc.ATLANTA, March 18 /PRNewswire/ -- Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) undergo multi-vessel...
|
|
|
New PLATO Sub-Analysis of CABG Patients Presented at ACC
ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes...
|
|
|
Primary results of CABG sub-analysis presented at ACC meeting
AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes (ACS) who took the investigational oral...
|
|
|
BiomedReports: News and FDA Updates for AMAG (NASDAQ:AMAG), Anika (Nasdaq:ANIK), AstraZeneca (NYSE:AZN)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials...
|
|
|
News and FDA Updates for AMAG (NASDAQ:AMAG), Anika (Nasdaq:ANIK), AstraZeneca (NYSE:AZN)
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and...
|
|
|
ACC: Ticagrelor Is Promising Alternative to Clopidogrel
TUESDAY, March 16 (HealthDay News) -- The use of ticagrelor instead of clopidogrel in patients with acute coronary syndrome who undergo coronary artery bypass graft (CABG) surgery is associated with a lower likelihood of fatal outcomes, according to...
|
|
|
Research and Markets: Atherosclerosis or Coronary Artery Disease (CAD) - Drug Pipeline Analysis and Market Forecasts to 2016
Research and Markets: DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/d0f918/atherosclerosis_or) has announced the addition of GlobalData's new report "" to their offering.is an essential source of information and...
|
|
|
Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Companies mentioned in this article: OrbusNeich ATLANTA, March 17 /PRNewswire/ -- OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.Margo...
|
|
|
MAQUET Cardiovascular Makes CABG-Related Announcement
Use of Minimally Invasive VASOVIEW System from Maquet Decreases Risk of Leg Wound Infection While Providing Clinical Outcomes Comparable to Traditional Vein Harvesting Procedure MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies,...
|
|
|
MAQUET's VASOVIEW EVH reduces rates of leg infection in CABG patients
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that study results published in the January 2010 Annals of Thoracic Surgery demonstrated that coronary artery bypass graft (CABG) patients who...
|
|
|
New PLATO Sub-Analysis of CABG Patients Presented at ACC
ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer deaths in patients with acute coronary syndromes...
|
|
|
New PLATO Sub-Analysis of CABG Patients Presented at ACC
Companies mentioned in this article: AstraZeneca ATLANTA, March 16 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were fewer...
|
|
|
ACC: CABG Data Suggest Ticagrelor Benefit
University of Pennsylvania School of Medicine.Action Points Explain to patients that the drug described in this report, ticagrelor, is not approved by the FDA. It is not availalbe for clinical use. Note that this study was published as an abstract and...
|
|
|
MAIN-COMPARE: Stenting Sustains Safety Outcomes Through 5 Years
ATLANTA, GAPatients with unprotected left main disease continue to experience similar risk of death and other safety outcomes through 5 years whether they undergo percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG),...
|
